CMG002

a PI3K-mTOR dual inhibitor

Also Known As:

Isopropyl 4-(6-(6-chloro-5-(2,4-difluorophenylsulfonamido)pyridine-3-yl)pyrido(3,2-d) pyrimidin-4-ylamino)piperidine-1-carboxylate; Propan-2-yl 4-((6-(6-chloro-5-((2,4-difluorophenyl)sulfonylamino)pyridin-3-yl)pyrido(3,2-d)pyrimidin-4-yl)amino)piperidine-1-carboxylate

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds

Experts

1.	Kim, Jin Sung: 2 articles (10/2019 - 01/2019)
2.	Hwang, Seong Gyu: 1 article (10/2019)
3.	Kim, Mi Na: 1 article (10/2019)
4.	Lee, Seung Min: 1 article (10/2019)
5.	An, Hee Jung: 1 article (01/2019)
6.	Cho, Hyeon Ju: 1 article (01/2019)
7.	Choi, Hye Joung: 1 article (01/2019)
8.	Heo, Jin Hyung: 1 article (01/2019)
9.	Jeong, Ju Yeon: 1 article (01/2019)
10.	Kim, Se Hwa: 1 article (01/2019)

Related Diseases

1.	Hepatocellular Carcinoma (Hepatoma) 10/01/2019 - "Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma."
2.	Neoplasms (Cancer) 10/01/2019 - "CMG002 inhibited HCC cell proliferation, induced apoptosis, and decreased tumor angiogenesis. " 10/01/2019 - "Treatment with CMG002 for 4 weeks alone and in combination with sorafenib strongly inhibited tumor growth. " 01/01/2019 - "In vivo xenograft studies revealed that treatment with CMG002, either alone or in combination with paclitaxel or cisplatin, led to a marked reduction in tumor growth. "
3.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2019 - "The aim of this study was to examine the effect of a newly developed PI3K/mTOR dual inhibitor, CMG002, on chemoresistant ovarian cancer cells. " 01/01/2019 - "Taken together, CMG002, a very potent PI3K/mTOR dual inhibitor, induced cytotoxicity in chemoresistant ovarian cancer cells, suggesting that this novel inhibitor might be a new therapeutic strategy for chemoresistant ovarian cancer." 01/01/2019 - "CMG002 showed marked toxicity against chemoresistant ovarian cancer cells and re-sensitized these cells to chemotherapeutic agents by suppressing cell proliferation and inducing G1 cell cycle arrest and apoptosis. " 01/01/2019 - "A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer." 01/01/2019 - "We examined the effects of CMG002, and its synergistic effects when combined with paclitaxel or cisplatin, on cell viability, cell cycle arrest, and apoptosis of PTX-resistant SKpac17 or cisplatin-resistant A2780cis ovarian cancer cells in vitro. "
4.	Carcinogenesis 10/01/2019 - "The combination of CMG002 and sorafenib significantly inhibited HCC cell proliferation and tumorigenesis by inhibiting the Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. "

Related Drugs and Biologics

1.	Sorafenib (BAY 43-9006)
2.	Paclitaxel (Taxol)
3.	Cisplatin (Platino)